Sharemaestro company-news research for Biohaven Ltd. (BHVN), showing current tone, evidence confidence, direct company coverage, sector and industry context, completed price response and the source headlines used on the page. Scores describe published news evidence. Confidence describes the amount, freshness, source breadth and direct company relevance of that evidence. Price context is shown separately.

NYSE United States Measured evidence

Company news sentiment

Latest BHVN news and sentiment

Biohaven Ltd.

Company headlines from the last 30 days, weighted by freshness, relevance, publisher quality and the strength of the wording. Price is shown separately.

Full chart Weekly report Factor research Options activity RSS feed
30-day score53Neutral is 50
Balanced news tone 38/100 evidence confidence 92% direct company focus 46 current stories across 13 publishers
Latest weekly closeUSD 15.41week of 28 Aug 2026
Main news subjectEarnings78/100 share of current news
News data statusHealthy38 duplicate stories removed

Current company news

Balanced news tone

The score uses 46 current company stories from 13 publishers.

Observed headline tone56/100 Published 30-day score53/100

Older, less relevant and less reliable stories count for less. Confidence is shown separately.

Latest source headline Why Biohaven Stock Was Rocking the Market This Week Motley Fool · 28 Aug 2026 07:32

What supports the score

Direct evidence

46 current stories are mapped specifically to BHVN.

Source breadth

The score uses 13 publishers rather than depending on one outlet.

Story agreement

The current stories agree at 79/100.

What limits the score

Price disagreement

Price is moving more forcefully than the current news tone suggests.

53/100
News scoreBalanced news tone
38/100
Confidencethin evidence
92%/100
Company news46 company stories
79/100
Story agreement21/100 difference

News history

Daily score and story count over 30 days

Daily weighted evidence
01 Aug: 2 stories02 Aug: 1 stories03 Aug: 2 stories06 Aug: 3 stories07 Aug: 2 stories09 Aug: 3 stories10 Aug: 4 stories11 Aug: 3 stories12 Aug: 1 stories14 Aug: 4 stories15 Aug: 1 stories16 Aug: 1 stories19 Aug: 1 stories21 Aug: 1 stories22 Aug: 2 stories24 Aug: 2 stories25 Aug: 3 stories26 Aug: 5 stories27 Aug: 2 stories28 Aug: 1 stories 01 Aug: tone 21, 2 stories02 Aug: tone 43, 1 stories03 Aug: tone 50, 2 stories06 Aug: tone 50, 3 stories07 Aug: tone 50, 2 stories09 Aug: tone 74, 3 stories10 Aug: tone 40, 4 stories11 Aug: tone 51, 3 stories12 Aug: tone 72, 1 stories14 Aug: tone 47, 4 stories15 Aug: tone 70, 1 stories16 Aug: tone 58, 1 stories19 Aug: tone 46, 1 stories21 Aug: tone 50, 1 stories22 Aug: tone 38, 2 stories24 Aug: tone 55, 2 stories25 Aug: tone 50, 3 stories26 Aug: tone 47, 5 stories27 Aug: tone 73, 2 stories28 Aug: tone 50, 1 stories 95505
01 Aug16 Aug30 Aug
News scoreStory count50 baseline

Confidence

How reliable the score is

Separate from direction

Confidence uses the amount of news, separate publishers, direct company relevance, freshness and agreement. A high or low score is not automatically reliable.

Amount of evidence19
0.964 after freshness weighting
Source breadth100
13 independent publishers
Company relevance92
share tied directly to this company
Freshness39
recency-weighted evidence
Agreement79
how closely stories agree
Publisher mix87
less reliance on one publisher

Price and news history

Weekly price and news-score history

Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

26 completed price weeks17 comparable news-score weeks
One scoring method across the chart.Stored company headlines are recalculated at each weekly point with the current 30-day freshness weighting. Old published snapshots are left unchanged.
06 Mar 2026: close 9.92, indexed 100.013 Mar 2026: close 9.58, indexed 96.620 Mar 2026: close 8.93, indexed 90.027 Mar 2026: close 8.37, indexed 84.403 Apr 2026: close 9.8, indexed 98.810 Apr 2026: close 9.17, indexed 92.417 Apr 2026: close 10.98, indexed 110.724 Apr 2026: close 9.88, indexed 99.601 May 2026: close 9.63, indexed 97.108 May 2026: close 9.86, indexed 99.415 May 2026: close 8.76, indexed 88.322 May 2026: close 9.45, indexed 95.329 May 2026: close 11.01, indexed 111.005 Jun 2026: close 10.8, indexed 108.912 Jun 2026: close 11.28, indexed 113.719 Jun 2026: close 13.57, indexed 136.826 Jun 2026: close 15.83, indexed 159.603 Jul 2026: close 15.96, indexed 160.910 Jul 2026: close 15.55, indexed 156.817 Jul 2026: close 15.44, indexed 155.624 Jul 2026: close 14.32, indexed 144.431 Jul 2026: close 13.5, indexed 136.107 Aug 2026: close 14.66, indexed 147.814 Aug 2026: close 14.64, indexed 147.621 Aug 2026: close 13.85, indexed 139.628 Aug 2026: close 15.41, indexed 155.3 08 May 2026: news score 50, close 9.86, 3 stories5015 May 2026: news score 50, close 8.76, 3 stories22 May 2026: news score 49, close 9.45, 4 stories29 May 2026: news score 52, close 11.01, 5 stories5205 Jun 2026: news score 51, close 10.8, 2 stories12 Jun 2026: news score 50, close 11.28, 2 stories19 Jun 2026: news score 50, close 13.57, 2 stories5026 Jun 2026: news score 51, close 15.83, 8 stories03 Jul 2026: news score 50, close 15.96, 10 stories10 Jul 2026: news score 50, close 15.55, 13 stories5017 Jul 2026: news score 50, close 15.44, 18 stories24 Jul 2026: news score 50, close 14.32, 19 stories31 Jul 2026: news score 50, close 13.5, 30 stories5007 Aug 2026: news score 48, close 14.66, 38 stories14 Aug 2026: news score 51, close 14.64, 51 stories21 Aug 2026: news score 52, close 13.85, 45 stories5228 Aug 2026: news score 52, close 15.41, 47 stories52 Price index 170.1 122.6 75.2 News score 100 50 0
06 Mar02 Jun28 Aug
Weekly close, indexedSentiment score
26-week price+55.3%latest close 15.41
News score change+2first to latest comparable week
One-week response+11.3%Price confirming higher
Fair-value position-42.9%Below fair value
WeekNews scoreCloseWeekly move
28 Aug 202652USD 15.41+11.3%
21 Aug 202652USD 13.85-5.4%
14 Aug 202651USD 14.64-0.1%
07 Aug 202648USD 14.66+8.6%
31 Jul 202650USD 13.5-5.7%
24 Jul 202650USD 14.32-7.3%
17 Jul 202650USD 15.44-0.7%
10 Jul 202650USD 15.55-2.6%
Value support

News subjects

What is shaping the score

Earnings
Earnings4425 stories · 54%
Market update509 stories · 20%
Deals and strategy618 stories · 17%
Analyst action603 stories · 7%
Balance sheet761 stories · 2%

Source mix

Where the evidence comes from

87/100 independence
MarketBeat479 stories · 20%
vinanet.vn315 stories · 11%
Investing.com753 stories · 7%
Simply Wall Street342 stories · 4%
PR Newswire552 stories · 4%
Stock Titan472 stories · 4%
finance.yahoo.com502 stories · 4%

Recurring subjects

Subjects appearing most often

Current evidence
Life Sciences26Earnings20Financial Markets18Finance10Technology4Epilepsy2Clinical Trials2Biotech2Biopharmaceuticals2Balance Sheet2

Earlier readings

How the score has changed

50 comparable readings · 117 days
Past and present use the same method.Each point recalculates the previous 30 days of stored company headlines with today's scoring rules. The original stored snapshots remain unchanged.
Comparable move+250 to 52 · Broadly stable
Observed range46–5450 is the neutral baseline
Evidence depth45stories at latest stored reading · +44
Confidence34/100Provisional · +34
04 May50 neutral30 Aug 05:05
ConstructiveBalanced or withheldCautious

Changes in the stored score

Scores are rebuilt from stored headlines with the current 30-day method. Days with no change are collapsed.

ObservedScoreMoveConfidenceStoriesStatus
30 Aug 05:0552+034/100 (-2)45 (-2)Provisional
28 Aug 23:5952+036/100 (-3)47 (0)Measured
27 Aug 23:5952+339/100 (+2)47 (+1)Measured
26 Aug 23:5949-137/100 (+5)46 (-4)Measured
25 Aug 23:5950+032/100 (-2)50 (+2)Provisional
24 Aug 23:5950+134/100 (+1)48 (+1)Provisional
22 Aug 23:5949-333/100 (+4)47 (+2)Provisional
21 Aug 23:5952+029/100 (-3)45 (-1)Provisional

Source headlines

The news behind the score

Showing 1-30 of 46

Only company-specific stories enter this score. The latest 30 days are shown newest first, with newer stories weighted more heavily and duplicate coverage combined.

#1—Not directional
Motley FoolDirect company coverageScored from headline

Why Biohaven Stock Was Rocking the Market This Week

Published
28 Aug 2026 07:32
News subject
Market update
Why this score
The headline reports news without a clear direction
Company focus
Shared story · 78%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 1.3d old
Duplicates
1 consolidated
#2—Not directional
Pharmaceutical TechnologyDirect company coverageScored from headline

SK inks $795m Biohaven epilepsy deal, entering potassium channel opener race

Published
27 Aug 2026 14:40
News subject
Deals and strategy
Why this score
The headline reports news without a clear direction
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 2.0d old
Duplicates
1 consolidated
#380Tone
ZacksDirect company coverageStored article

BHVN Stock Soars 18% on $795M Out-Licensing Deal for Epilepsy Program

Biohaven BHVN stock climbed 17.9% on Wednesday after the announcement of a strategic global licensing and collaboration agreement with South Korea-based SK Biopharmaceuticals. Under the deal, SK Biopharmaceuticals will receive exclusive worldwide rights to Biohaven's Kv7 ion channel platform, led by opakalim (BHV-7000), undergoing mid- to late-stage development for focal epilepsy. Under the terms, SK Biopharmaceuticals will provide upfront and milestone payments of up to $795 million related to the Kv7 platform. Biohaven will receive $400 million in cash consideration, including $350 million p

Balance SheetBiotechEarnings Per ShareEpilepsyM APartnership
Published
27 Aug 2026 13:42
News subject
Deals and strategy
Why this score
Large positive market reaction, Positive market reaction
Company focus
Shared story · 78%
How it is used
Direct company coverage
Story strength
High · 72/100
30-day weight
21.2% of the score · 2.0d old
Duplicates
3 consolidated
#4—Not directional
MT NewswiresDirect company coverageScored from headline

Update: Biohaven Shares Rise After Epilepsy Drug Licensing Deal

Published
26 Aug 2026 18:29
News subject
Deals and strategy
Why this score
The headline reports news without a clear direction
Company focus
Shared story · 78%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 2.8d old
Duplicates
1 consolidated
#567Tone
InvestorsHubDirect company coverageScored from headline

Biohaven shares climb 7% after signing major SK Biopharmaceuticals licensing deal

Published
26 Aug 2026 12:28
News subject
Deals and strategy
Why this score
Positive market reaction, Large positive market reaction
Company focus
Shared story · 78%
How it is used
Direct company coverage
Story strength
Medium · 54/100
30-day weight
10.7% of the score · 3.1d old
Duplicates
1 consolidated
#657Tone
BioPharma DiveDirect company coverageScored from headline

Biohaven trades cash for ‘upside’ with $795M epilepsy drug deal

Published
26 Aug 2026 11:17
News subject
Deals and strategy
Why this score
Positive financial language
Company focus
Shared story · 78%
How it is used
Direct company coverage
Story strength
Medium · 42/100
30-day weight
6% of the score · 3.1d old
Duplicates
1 consolidated
#7—Not directional
finance.yahoo.comDirect company coverageStored article

Biohaven and SK Biopharmaceuticals Enter into Strategic Global Licensing Agreement for Novel Kv7 Ion Channel Platform and Opakalim, Lead Candidate for Epilepsy

SK Biopharmaceuticals to provide upfront and milestone payments related to the Kv7 platform up to $795 million, along with tiered royalties to Biohaven ranging from the mid-teens to low twenties on U.S. net sales of opakalim. Opakalim, the lead candidate from Biohaven's Kv7 platform, is a next-generation, selective Kv7.2/7.3 potassium channel activator currently in Phase 2/3 development for focal epilepsy, with topline results from the RISE3 trial expected in 2H 2026. It is designed to offer an easy-to-use, once-daily oral treatment without the need for titration and a low incidence of burdens

Balance SheetBiopharmaceuticalsEpilepsyLicensing Agreement
Published
26 Aug 2026 06:01
News subject
Earnings
Why this score
The headline reports news without a clear direction
Company focus
Shared story · 78%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 3.3d old
Duplicates
1 consolidated
#9—Not directional
Investing.com CanadaDirect company coverageStored article

Biohaven, Yale win $4M judgment in trade secret case By Investing.com

Biohaven Ltd. and Yale University have been awarded a combined $4 million judgment in a trade secret misappropriation and breach of contract lawsuit against Avilar Therapeutics, Inc. and RA Capital Management GP, LLC. The judgment follows a jury verdict which found that RA Capital and Avilar willfully and maliciously misappropriated Yale's MODA targeted protein degradation platform trade secret and that RA Capital breached a 2019 confidentiality agreement with Yale. Yale received $2 million for the breach of contract and $1 million each from both Biohaven and Yale for trade secret misappropriation.

FinanceLife Sciences
Published
25 Aug 2026 20:44
News subject
Deals and strategy
Why this score
Legal or regulatory risk
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 3.7d old
Duplicates
1 consolidated
#10—Not directional
PR NewswireDirect company coverageStored article

Federal Court Enters Judgment Confirming RA Capital and Avilar Therapeutics Willfully and Maliciously Misappropriated Trade Secret Developed at Yale, Formalizing $4 Million Award to Biohaven and Yale University

A U.S. District Court in Delaware has formalized a $4 million award to Biohaven Ltd. and Yale University, ruling that RA Capital Management GP, LLC and Avilar Therapeutics, Inc. willfully and maliciously misappropriated a trade secret related to Yale's "MODA" protein degradation platform. The judgment confirms a jury's verdict, with $2 million awarded to Yale for RA Capital's breach of contract and $1 million each to Yale and Biohaven for trade secret misappropriation. Biohaven had licensed the MODA platform from Yale and pursued litigation after RA Capital allegedly used confidential information to establish a competing company, Avilar, rather than partnering with Yale.

FinanceLife Sciences
Published
25 Aug 2026 20:44
News subject
Deals and strategy
Why this score
Contract or approval won
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 3.7d old
Duplicates
1 consolidated
#11—Not directional
StocktwitsDirect company coverageScored from headline

BHVN Stock On Track For Best Day In Over 2 Months After SK Biopharmaceuticals Licenses Epilepsy Drug: Retail Now Awaits Obesity Trial Readout

Published
25 Aug 2026 13:30
News subject
Market update
Why this score
The headline reports news without a clear direction
Company focus
Shared story · 78%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 4.0d old
Duplicates
2 consolidated
#1357Tone
SahmDirect company coverageStored article

Is Biohaven (BHVN) Undervalued Following Its Latest Earnings Loss Improvement?

Biohaven (BHVN) reported improved Q2 2026 earnings, reducing its net loss to US$137.31 million. While the stock's price-to-book ratio of 171.2x suggests overvaluation compared to industry averages, a Discounted Cash Flow (DCF) model from Simply Wall St indicates the shares might be significantly undervalued at $13.85, estimating a future cash flow value of $53.83 per share. The article highlights the conflicting valuation perspectives, urging investors to consider both the risks of a loss-making biotech and the potential of its pipeline.

EarningsFinanceFinancial MarketsLife Sciences
Published
24 Aug 2026 09:16
News subject
Earnings
Why this score
Positive valuation view, Improving financial comparison
Company focus
Main company · 100%
How it is used
Direct company coverage
Story strength
Medium · 43/100
30-day weight
10.2% of the score · 5.2d old
Duplicates
1 consolidated
#1434Tone
Simply Wall StreetDirect company coverageStored article

Why Biohaven (BHVN) Is Down 9.1% After Reporting Narrower Q2 and H1 Net Losses

Biohaven Ltd. reported narrower net losses for Q2 and H1 2026, with Q2 losses at US$137.31 million and H1 losses at US$267.84 million. Despite this, the company's shares dropped 9.1%, and concerns remain regarding its cash burn, reliance on future capital raises, and whether its significant pipeline can justify current spending. Investors are advised to consider various perspectives and the company's financial health before making investment decisions.

EarningsFinancial MarketsLife Sciences
Published
22 Aug 2026 13:13
News subject
Earnings
Why this score
Negative market reaction, Large negative market reaction
Company focus
Main company · 100%
How it is used
Direct company coverage
Story strength
Medium · 50/100
30-day weight
9.5% of the score · 7.0d old
Duplicates
1 consolidated
#15—Not directional
TradingViewDirect company coverageStored article

Price to earnings forward of Biohaven Ltd. – NYSE:BHVN

This article provides financial information for Biohaven Ltd. (NYSE: BHVN), specifically focusing on its forward price-to-earnings ratio. The content appears to be a page from a financial data platform, displaying the company's ticker, exchange, and a placeholder for the "Price to earnings forward" value.

EarningsFinancial MarketsLife Sciences
Published
22 Aug 2026 01:37
News subject
Earnings
Why this score
The headline reports news without a clear direction
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 7.5d old
Duplicates
1 consolidated
#16—Not directional
MarketBeatDirect company coverageScored from headline

HC Wainwright Decreases Earnings Estimates for Biohaven

Published
21 Aug 2026 12:45
News subject
Earnings
Why this score
The headline reports news without a clear direction
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 8.1d old
Duplicates
1 consolidated
#17—Not directional
MarketBeatDirect company coverageStored article

Biohaven Ltd. (NYSE:BHVN) Receives Consensus Rating of "Moderate Buy" from Brokerages

Biohaven Ltd. (NYSE:BHVN) has received a "Moderate Buy" consensus rating from seventeen research firms, with an average 12-month price target of $21.75. The company's shares opened at $13.59, and it recently reported a quarterly EPS of negative $0.91, missing the consensus estimate. Institutional investors hold 88.78% of the stock, and analysts anticipate a full-year loss of approximately $3.11 per share.

EarningsFinanceFinancial MarketsLife Sciences
Published
19 Aug 2026 06:32
News subject
Analyst action
Why this score
Negative financial language
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 10.3d old
Duplicates
1 consolidated
#1858Tone
MarketBeatDirect company coverageStored article

Biohaven Ltd. $BHVN Shares Bought by Quantinno Capital Management LP

Quantinno Capital Management LP significantly increased its stake in Biohaven Ltd. (BHVN) by 190% in the first quarter, bringing its total to 121,554 shares. Several other institutional investors also expanded their positions, contributing to the high institutional ownership of 88.78%. Despite a reported quarterly loss of $0.91 per share, analysts maintain a "Moderate Buy" rating with a consensus price target of $21.75, considerably higher than the stock's recent trading price.

EarningsFinanceFinancial MarketsLife Sciences
Published
16 Aug 2026 12:10
News subject
Earnings
Why this score
Institutional or insider buying
Company focus
Main company · 100%
How it is used
Direct company coverage
Story strength
Medium · 36/100
30-day weight
3% of the score · 13.1d old
Duplicates
1 consolidated
#1970Tone
simplywall.stDirect company coverageStored article

Biohaven (BHVN) Could Be 73% Undervalued As Regeneron Deal Expands

Biohaven (BHVN) is gaining attention after expanding its oncology collaboration with Regeneron Pharmaceuticals. Despite a recent slight easing in share price, the stock shows strong 90-day returns, contrasting with weaker long-term performance. A discounted cash flow (DCF) model by Simply Wall St suggests Biohaven could be 73% undervalued, estimating a fair value of $54.53 against its current trading price of $14.64, although its high P/B ratio indicates significant valuation risk.

EarningsFinancial MarketsLife Sciences
Published
15 Aug 2026 18:40
News subject
Earnings
Why this score
Positive valuation view
Company focus
Main company · 100%
How it is used
Direct company coverage
Story strength
Medium · 49/100
30-day weight
4.1% of the score · 13.8d old
Duplicates
1 consolidated
#2033Tone
Simply Wall StreetDirect company coverageStored article

Is Biohaven’s Narrowing Losses and AI Board Hire Altering The Investment Case For Biohaven (BHVN)?

Biohaven Ltd. reported narrowing losses in Q2 2026, with a net loss of US$137.31 million, and appointed AI-focused investor John Yetimoglu to its Board. Despite these developments, the company still faces significant financial risk due to zero revenue, heavy ongoing losses, and a short cash runway, with investors needing to consider future funding and potential dilution. The article suggests that while the AI appointment aligns with Biohaven's data-driven R&D, it doesn't immediately alter the key value drivers of its epilepsy and MoDE degrader programs.

EarningsFinanceFinancial MarketsLife SciencesTechnology
Published
14 Aug 2026 23:10
News subject
Earnings
Why this score
Dilution risk
Company focus
Main company · 100%
How it is used
Direct company coverage
Story strength
Medium · 45/100
30-day weight
3% of the score · 14.6d old
Duplicates
1 consolidated
#21—Not directional
finance.yahoo.comDirect company coverageStored article

Is Biohaven (BHVN)’s Latest Regeneron Pharmaceuticals (REGN) Deal a Major Catalyst for its Pipeline?

Two prominent biopharmaceutical names, Biohaven Ltd. (NYSE:BHVN) and Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), are deepening their relationship across oncology. On July 20, Biohaven announced a clinical supply agreement with Regeneron to evaluate the combination of BHV-1530 and Regeneron's cemiplimab (Libtayo) in patients with solid tumors. BHV-1530's novel topoisomerase I (TopoIx) payload generates immunogenic cell death and triggers antitumor immune responses, creating a compelling rationale when paired with checkpoint inhibition. Building on an earlier agreement for BHV-1510, a TROP2-d

BiotechClinical TrialsEarningsNet IncomePharmaPrice Target
Published
14 Aug 2026 22:23
News subject
Earnings
Why this score
The headline reports news without a clear direction
Company focus
Shared story · 78%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 14.7d old
Duplicates
1 consolidated
#22—Not directional
Stock TitanDirect company coverageStored article

Woodline Partners (BHVN) discloses 5.1% beneficial stake in Biohaven

Woodline Partners LP has reported a beneficial ownership of 5.1% in Biohaven Ltd., amounting to 7,660,280 Common Shares. This ownership grants Woodline Partners sole voting and dispositive power over these shares, which are held through Woodline Master Fund LP and Woodline Spire Master Fund LP. The stake is based on Biohaven's 150,560,990 Common Shares outstanding as of April 30, 2026.

Financial MarketsLife Sciences
Published
14 Aug 2026 15:12
News subject
Deals and strategy
Why this score
The headline reports news without a clear direction
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 15.0d old
Duplicates
1 consolidated
#2360Tone
MarketBeatDirect company coverageStored article

Renaissance Technologies LLC Acquires New Position in Biohaven Ltd. $BHVN

Renaissance Technologies LLC has acquired a new position in Biohaven Ltd. (NYSE:BHVN), purchasing 160,952 shares valued at approximately $1.36 million. This move comes as institutional investors collectively own 88.78% of Biohaven, with several major funds significantly increasing their stakes. Despite missing quarterly EPS expectations, analysts maintain a "Moderate Buy" rating with an average price target of $21.75 for Biohaven.

EarningsFinancial MarketsLife Sciences
Published
14 Aug 2026 11:12
News subject
Earnings
Why this score
Institutional or insider buying
Company focus
Main company · 100%
How it is used
Direct company coverage
Story strength
Medium · 38/100
30-day weight
2.5% of the score · 15.1d old
Duplicates
1 consolidated
#2472Tone
The Globe and MailDirect company coverageStored article

Bank of America Securities Reaffirms Their Buy Rating on Biohaven Ltd. (BHVN)

Bank of America Securities has reiterated a Buy rating on Biohaven Ltd. (BHVN) with a price target of $11.00, despite the stock closing higher at $14.54. Analyst Dina Ramadane, who covers the Healthcare sector, has a 61.54% success rate on her recommendations. The broader analyst consensus for Biohaven Ltd. is a Moderate Buy with an average price target of $16.33.

EarningsFinancial MarketsLife Sciences
Published
12 Aug 2026 07:00
News subject
Analyst action
Why this score
Buy Rating
Company focus
Main company · 100%
How it is used
Direct company coverage
Story strength
Medium · 46/100
30-day weight
0.4% of the score · 17.3d old
Duplicates
1 consolidated
#2575Tone
Investing.comDirect company coverageStored article

Biohaven Pharma stock price target raised to $23 by RBC Capital

RBC Capital has raised its price target for Biohaven Pharma (NYSE:BHVN) to $23 from $22, maintaining an Outperform rating, following the company's second-quarter 2026 earnings report. The firm highlights potential opportunities in troriluzole and degrader data, estimating a more than $4 billion market by 2035, and anticipates success in the near-term Kv7 readout. Despite some elevated spending and concerns about cash burn, the pipeline is deemed attractive, and the company is progressing with other trials like RISE3 for epilepsy and a Phase 3 trial for Graves’ disease.

EarningsFinancial MarketsLife Sciences
Published
11 Aug 2026 14:44
News subject
Analyst action
Why this score
Analyst upgrade
Company focus
Main company · 100%
How it is used
Direct company coverage
Story strength
Medium · 49/100
30-day weight
0.5% of the score · 18.0d old
Duplicates
1 consolidated
#26—Not directional
vinanet.vnDirect company coverageScored from headline

Biohaven (BHVN) Holds Near Key Support After Modest Pullback - Pre-Earnings Momentum

Published
11 Aug 2026 07:00
News subject
Market update
Why this score
The headline reports news without a clear direction
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 18.3d old
Duplicates
1 consolidated
#2741Tone
Stock TitanDirect company coverageStored article

Biohaven (NYSE: BHVN) reports $267.8M H1 2026 loss and $267.9M in liquidity

Biohaven Ltd. (NYSE: BHVN), a clinical-stage biopharmaceutical company, reported a net loss of $267.8 million for the first half of 2026, primarily due to $204.6 million in research and development expenses. The company maintains liquidity with $267.9 million in cash, cash equivalents, and marketable securities, which management expects to fund operations for at least one year. Biohaven is focused on advancing its R&D portfolio across immunology, obesity, neuroscience, and oncology, including key clinical programs such as Kv7 ion channel modulation for epilepsy and Molecular Degrader of Extracellular Proteins (MoDE) for immunological diseases.

EarningsLife Sciences
Published
11 Aug 2026 06:15
News subject
Earnings
Why this score
Negative financial language
Company focus
Main company · 100%
How it is used
Direct company coverage
Story strength
Low · 34/100
30-day weight
1.2% of the score · 18.3d old
Duplicates
1 consolidated
#2816Tone
MarketBeatDirect company coverageStored article

Biohaven (NYSE:BHVN) Posts Quarterly Earnings Results, Misses Estimates By $0.02 EPS

Biohaven (NYSE:BHVN) announced its quarterly earnings, reporting a loss of $0.78 per share, which missed analysts' consensus estimates by $0.02. Following the announcement, shares of Biohaven dropped 0.5% to $14.58. Despite the earnings miss, analyst sentiment for Biohaven remains a "Moderate Buy" with an average price target of $21.62.

EarningsFinancial MarketsLife Sciences
Published
10 Aug 2026 23:15
News subject
Earnings
Why this score
Missed expectations, Negative market reaction, Large negative market reaction
Company focus
Main company · 100%
How it is used
Direct company coverage
Story strength
High · 63/100
30-day weight
3.2% of the score · 18.6d old
Duplicates
1 consolidated
#2960Tone
MarketBeatDirect company coverageStored article

Biohaven Ltd. $BHVN Shares Purchased by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company increased its stake in Biohaven Ltd. (NYSE:BHVN) by 52.5% in Q1, now owning 202,975 shares valued at $1.72 million. Other institutional investors also significantly increased their holdings, with hedge funds and institutional investors collectively owning 88.78% of the stock. Analysts currently rate Biohaven as a "Moderate Buy" with an average price target of $21.62.

EarningsFinancial MarketsLife Sciences
Published
10 Aug 2026 20:09
News subject
Earnings
Why this score
Institutional or insider buying
Company focus
Main company · 100%
How it is used
Direct company coverage
Story strength
Medium · 37/100
30-day weight
1.5% of the score · 18.8d old
Duplicates
1 consolidated
#3066Tone
Kalkine MediaDirect company coverageStored article

Biohaven Ltd. Announces Q2 2026 Financial Results Highlighting Reduced Losses and R&D Spending

Biohaven Ltd. has filed its Q2 2026 financial report, revealing continued operating losses but also a reduction in research and development spending compared to the previous year. This report covers the three- and six-month periods ending June 30, 2026. The full details are available via an SEC Form 10-Q filing.

EarningsLife Sciences
Published
10 Aug 2026 14:16
News subject
Earnings
Why this score
Loss narrowed
Company focus
Main company · 100%
How it is used
Direct company coverage
Story strength
Medium · 42/100
30-day weight
1.5% of the score · 19.0d old
Duplicates
1 consolidated

Earlier company news

BHVN news archive

Showing 1-30 of 48 stored headlines

Stored newest first for historical research. It starts after the newest three pages above and then continues through older news. Each archive page is loaded only when it is opened.

Jul 30 2026
TradingKeyArchivedNeutral tone

Biohaven Ltd (BHVN) Cash Flow

This article provides a detailed quarterly and annual cash flow statement for Biohaven Ltd (BHVN), covering operating, investing, and financing activities. It also includes frequently asked questions explaining different types of cash flow and Biohaven's specific cash flow figures for operating, investing, financing, and free cash flow in recent periods. The data aims to help users evaluate the company's financial soundness and stability.

EarningsFinanceLife Sciences
Published
30 Jul 2026 10:41
Catalyst
Earnings
Coverage
Direct company
Duplicates
1 consolidated
Jul 29 2026
Simply Wall StArchivedPositive tone

Biohaven (BHVN) Following Its Court Win Still Looks Cheap Against Fair Value

Biohaven (BHVN) recently won a federal jury case related to misappropriated trade secrets, yet its share price has seen a short-term decline despite strong 90-day and year-to-date gains. A Discounted Cash Flow (DCF) model estimates Biohaven's fair value at $61.24, significantly higher than its current trading price of $13.77, suggesting it is undervalued. However, the company faces risks due to a lack of current revenue and potential clinical trial setbacks, and its high Price-to-Book ratio of 16x raises questions about how much future success is already factored into its valuation.

EarningsFinanceFinancial MarketsLife Sciences
Published
29 Jul 2026 13:40
Catalyst
Earnings
Coverage
Direct company
Duplicates
1 consolidated
Jul 28 2026
Investing.comArchivedNeutral tone

Biohaven and Yale win $4M verdict in trade secret case

A federal jury awarded Biohaven Ltd. and Yale University $4 million in a trade secret misappropriation case against Avilar Therapeutics, Inc. and RA Capital Management GP, LLC. The jury found that Avilar and RA Capital willfully and maliciously misappropriated a Yale trade secret related to its MODA targeted protein degradation platform and that RA Capital breached its 2019 confidentiality agreement with Yale. The damages include $2 million to Yale for breach of contract and $1 million each to Yale and Biohaven for trade secret misappropriation.

FinanceLife Sciences
Published
28 Jul 2026 09:40
Catalyst
Deals and strategy
Coverage
Direct company
Duplicates
1 consolidated
Jul 27 2026
Law360ArchivedNeutral tone

Yale, Biohaven Win $4M In Biotech Trade Secret Trial

A Delaware federal jury has awarded Yale University and Biohaven Therapeutics $4 million in a biotech trade secret trial. The verdict found that venture capital firm RA Capital Management GP breached a confidentiality agreement and, along with Avilar Therapeutics, misappropriated a Yale-developed trade secret for designing protein-degrading drug molecules.

FinanceLife Sciences
Published
27 Jul 2026 20:11
Catalyst
Market update
Coverage
Direct company
Duplicates
1 consolidated
Jul 27 2026
Bloomberg Law NewsArchivedNeutral tone

Yale, Biohaven Win $4 Million Verdict Over Drug-Development Tech

Yale University and Biohaven Therapeutics Ltd. were jointly awarded $4 million in a Delaware trial. The verdict found Avilar Therapeutics Inc. and RA Capital Management GP LLC liable for misappropriating Yale's "MODA" drug-development trade secret and for breaching a confidentiality agreement. The jury specifically awarded Yale $2 million, with the total verdict reaching $4 million.

FinanceLife Sciences
Published
27 Jul 2026 18:10
Catalyst
Market update
Coverage
Direct company
Duplicates
1 consolidated
Jul 27 2026
finance.yahoo.comArchivedNeutral tone

Biohaven Awarded $1 Million Over Alleged Trade Secret Violations by Avilar Therapeutics, RA Capital Management

Biohaven (BHVN) said Monday that a federal jury has awarded it $1 million in damages over an alleged PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in

Published
27 Jul 2026 13:10
Catalyst
Analyst action
Coverage
Direct company
Duplicates
1 consolidated
Jul 27 2026
PR NewswireArchivedNeutral tone

Federal Jury Finds Avilar Therapeutics and RA Capital Willfully and Maliciously Misappropriated Trade Secret Developed at Yale, Awards Biohaven and Yale University $4 Million

A federal jury found Avilar Therapeutics and RA Capital Management GP, LLC guilty of willfully and maliciously misappropriating a trade secret developed at Yale University related to its "MODA" targeted protein degradation platform. RA Capital was also found to have breached a confidentiality agreement with Yale. The jury awarded Biohaven Ltd. and Yale University a combined $4 million in damages for trade secret misappropriation and breach of contract.

Life Sciences
Published
27 Jul 2026 12:10
Catalyst
Market update
Coverage
Direct company
Duplicates
1 consolidated
Jul 27 2026
SahmArchivedNeutral tone

How Biohaven’s (BHVN) Trade Secret Verdict Shapes Its Intellectual Property Defense Strategy

Biohaven recently won a US$1,000,000 trade secret lawsuit, reinforcing its commitment to protecting intellectual property. While this win strengthens the narrative around IP quality, it doesn't change the company's core investment risks, which include clinical outcomes, funding needs, and potential shareholder dilution. Biohaven remains a high-risk, pre-revenue biotech focused on its clinical pipeline.

EarningsLife Sciences
Published
27 Jul 2026 08:41
Catalyst
Regulatory and legal
Coverage
Direct company
Duplicates
1 consolidated
Jul 27 2026
TradingKeyArchivedNeutral tone

Biohaven Ltd (BHVN) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Biohaven Ltd (BHVN) stock, focusing on various indicators and moving averages. It presents a summary of buy, neutral, and sell signals derived from tools such as MACD, RSI, and different moving average periods. The analysis concludes with a neutral signal based on today's moving averages and other technical indicators.

Financial MarketsLife Sciences
Published
27 Jul 2026 08:10
Catalyst
Market update
Coverage
Direct company
Duplicates
1 consolidated
Jul 27 2026
TradingKeyArchivedNegative tone

BHVN|Biohaven Ltd|Price:14.320|Chg%:-0.320

This article provides a detailed financial overview of Biohaven Ltd (BHVN), including key financial indicators, income statements, balance sheets, and cash flow statements for various quarters and fiscal years. It highlights the company's latest earnings, revenue forecasts, and analyst ratings, presenting a comprehensive data dashboard for investors to analyze its market health. The report also includes FAQs addressing specific financial metrics from Biohaven Ltd's FY2025 earnings report.

EarningsFinanceFinancial MarketsLife Sciences
Published
27 Jul 2026 03:42
Catalyst
Earnings
Coverage
Direct company
Duplicates
1 consolidated
Jul 21 2026
StocktwitsArchivedNeutral tone

Biohaven Pharmaceutical Holding Company Ltd (BHVN) Earnings, Actual EPS, EPS Estimates & Results

This article provides detailed earnings information for Biohaven Pharmaceutical Holding Company Ltd (BHVN), including actual EPS, EPS estimates, and results. It highlights upcoming Q2 '26 earnings with an estimated EPS of -$0.75 and an estimated revenue of $0M. The company's historical quarterly performance shows a mix of missed and beat EPS estimates.

EarningsFinancial MarketsLife Sciences
Published
21 Jul 2026 06:11
Catalyst
Earnings
Coverage
Direct company
Duplicates
1 consolidated
Jul 20 2026
PR NewswireArchivedNeutral tone

Biohaven to Present New Clinical Data at ESMO Congress on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload

Biohaven Ltd. will present new Phase 1 clinical data on its FGFR3-directed antibody-drug conjugate (ADC) BHV-1530 at the ESMO Congress 2026. The data shows early tumor reductions in various advanced solid tumors with a differentiated safety profile, and Biohaven has also partnered with Regeneron to evaluate BHV-1530 in combination with cemiplimab. BHV-1530 aims to target FGFR3 regardless of alteration status, potentially expanding the addressable patient population beyond current FGFR tyrosine kinase inhibitors.

Clinical TrialsFda ApprovalLife SciencesOncology
Published
20 Jul 2026 12:10
Catalyst
Regulatory and legal
Coverage
Direct company
Duplicates
2 consolidated
Jul 18 2026
Simply Wall StreetArchivedNegative tone

How Biohaven’s (BHVN) R&D Leadership Shuffle Will Impact Investors

Biohaven Ltd. recently reshuffled its R&D leadership, with Chief Scientific Officer Bruce Car transitioning to a part-time Chief Innovation Officer role and David Pirman promoted to head of discovery. This reorganization aims to separate external innovation from internal discovery, which could clarify accountability but also centralizes scientific leadership in new management. While the changes don't immediately impact near-term clinical catalysts, investors should monitor the execution risk given Biohaven's zero revenue, short cash runway, and ongoing losses.

FinanceFinancial MarketsLife Sciences
Published
18 Jul 2026 06:14
Catalyst
Earnings
Coverage
Direct company
Duplicates
1 consolidated
Jul 18 2026
BitgetArchivedNeutral tone

Biohaven files Form 3 for Chief Legal Officer Warren Karl Volles

Biohaven's Chief Legal Officer, Warren Karl Volles, has filed a Form 3, disclosing ownership of 248,212 common shares and stock options for 731,000 shares. This disclosure was made public via the U.S. SEC's EDGAR system on July 17, 2026. The information was initially created by Public Technologies (PUBT) using generative AI for informational purposes.

FinanceLife Sciences
Published
18 Jul 2026 04:39
Catalyst
Market update
Coverage
Direct company
Duplicates
1 consolidated
Jul 17 2026
Stock TitanArchivedNeutral tone

Biohaven Ltd. (NYSE: BHVN) legal chief discloses holdings

Biohaven Ltd.'s Chief Legal Officer, Warren Karl Volles, has filed an initial statement of beneficial ownership, disclosing holdings including 248,212 Common Shares acquired directly and through an employee plan, 14,000 restricted share units, and various stock options totaling over 700,000 underlying common shares. These holdings and their vesting schedules were detailed in a recent SEC Form 3 filing. The filing outlines the exercise prices and expiration dates of the numerous stock options, with some portions already exercisable and others vesting through 2029, 2032, 2033, 2034, 2035, and 2036.

EarningsLife Sciences
Published
17 Jul 2026 23:11
Catalyst
Earnings
Coverage
Direct company
Duplicates
1 consolidated
Jul 17 2026
Quiver QuantitativeArchivedNeutral tone

Lobbying Update: $120,000 of BIOHAVEN LTD. lobbying was just disclosed

BIOHAVEN LTD. (BHVN) recently disclosed $120,000 in lobbying expenditures for Q2 2026, primarily focused on advocacy for patients with rare diseases. The article also details recent hedge fund activity, showing significant adds and removals of BHVN shares, and lists price targets from six analysts with a median target of $17.5.

FinanceFinancial MarketsLife Sciences
Published
17 Jul 2026 18:25
Catalyst
Analyst action
Coverage
Direct company
Duplicates
2 consolidated
Jul 17 2026
TradingViewArchivedNeutral tone

Price to book forward of Biohaven Ltd. – NYSE:BHVN

The article provides a brief financial snippet for Biohaven Ltd. (NYSE: BHVN), specifically focusing on its "Price to book forward" metric. It appears to be a data point derived from a financial platform, showing the value and change for this specific period. The content is sparse, primarily acting as a label for a financial data point.

FinanceFinancial Markets
Published
17 Jul 2026 17:10
Catalyst
Market update
Coverage
Direct company
Duplicates
1 consolidated
Jul 17 2026
Stock Traders DailyArchivedNeutral tone

Discipline and Rules-Based Execution in BHVN Response

This article provides an analysis of Biohaven Ltd. (BHVN) leveraging AI models to generate trading strategies across different risk profiles. It highlights near-term weak sentiment, identifies potential long-term weakness, and offers specific entry, target, and stop-loss levels for position trading, momentum breakout, and risk hedging strategies. The analysis is based on multi-timeframe signal analysis and institutional trading strategies.

Financial MarketsLife Sciences
Published
17 Jul 2026 12:09
Catalyst
Market update
Coverage
Direct company
Duplicates
1 consolidated
Jul 05 2026
FinvizArchivedLegacy headline · tone unscoredLegacy source lookup

BHVN - Biohaven Ltd Latest SEC Filings

Published
5 Jul 2026 16:00
Catalyst
Legacy snapshot
Coverage
Direct company
Duplicates
1 consolidated

Provider matches checked

Provider mentions not used in the score

1 not scored

A news provider linked these stories to BHVN, but the headline and available text are not mainly about Biohaven Ltd.. They are kept here for transparency and do not affect the score, confidence, history or wider market totals.

Provider mentions are kept separate

Open the list to see which provider matches were checked and left out of BHVN sentiment.

Open provider mentions

How the page works

How to read the score

The score shows direction

It describes the weighted balance of qualifying headlines. A score of 50 can mean balanced news or that there is not enough evidence; the status label explains which.

Confidence is separate

Confidence measures depth, source breadth, direct relevance, freshness and agreement. It does not rise merely because the tone is extreme.

Price is confirmation

Weekly price response, trend and fair-value position test whether the market is accepting or rejecting the news. They never rewrite the news score.

What the page does

It measures news already published. It is not a forecast, recommendation or price target.

Evidence context